Pfizer · NSE: PFIZER · BSE: 500680
Q4 FY21 results · Jan–Mar 2021
Pfizer reported revenue from operations of ₹534.76 crore (up 6.5% from Q4 FY20) and net profit of ₹100.55 crore (down 2.4% from Q4 FY20) for Q4 FY21 (Jan–Mar 2021), on a standalone basis.
| Item | Q4 FY21 | Q4 FY20 | YoY | Q3 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 534.76 | 502.01 | +6.5% | 593.49 | −9.9% |
| Other income | 37.20 | 45.22 | −17.7% | 14.57 | +155.3% |
| Total income | 571.96 | 547.23 | +4.5% | 608.06 | −5.9% |
| Profit before tax | 132.09 | 121.90 | +8.4% | 180.26 | −26.7% |
| Net profit for the period | 100.55 | 103.01 | −2.4% | 141.24 | −28.8% |
| EPS, basic (₹) | 21.98 | 22.52 | −2.4% | 30.87 | −28.8% |
| Net margin (%) | 18.8 | 20.5 | 23.8 |
Standalone
- Filed with BSE
- 26 May 2021, 19:25 IST
- Board meeting
- 26 May 2021
- Period
- 01 Jan 2021 to 31 Mar 2021
- Review status
- Audited
- Source
- XBRL filing on BSE